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Abstract. Glycogen synthase 2 (Gys-2) is the rate-
limiting enzyme in the storage of glycogen in liver and
adipose tissue, yet little is known about regulation of
Gys-2 transcription. The peroxisome proliferator-acti-
vated receptors (PPARs) are transcription factors in-
volved in the regulation of lipid and glucosemetabolism
andmight be hypothesized to govern glycogen synthesis
as well. Here, we show that Gys-2 is a direct target gene
of PPARa, PPARb/d and PPARg. Expression of Gys-2
is significantly reduced in adipose tissue of PPARa–/–,
PPARb/d–/– and PPARg+/– mice. Furthermore, syn-
thetic PPARb/d, and g agonists markedly up-regulate
Gys-2 mRNA and protein expression in mouse 3T3-L1
adipocytes. In liver, PPARa deletion leads to decreased
glycogen levels in the refed state, which is paralleled by
decreased expression of Gys-2 in fasted and refed state.
Two putative PPAR response elements (PPREs) were
identified in themouseGys-2 gene: one in the upstream
promoter (DR-1prom) and one in intron 1 (DR-1int). It
is shown that DR-1int is the response element for
PPARs, while DR-1prom is the response element for
Hepatic Nuclear Factor 4 alpha (HNF4a). In adipose
tissue, which does not express HNF4a, DR-1prom is
occupied by PPARb/d and PPARg, yet binding does not
translate into transcriptional activation of Gys-2. Over-
all, we conclude that mouse Gys-2 is a novel PPAR
target gene and that transactivation by PPARs and
HNF4a is mediated by two distinct response elements.
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Introduction
Metabolic syndrome describes a combination of
metabolic abnormalities that include central obesity,
dyslipidemia, hypertension, insulin resistance, and a
pro-inflammatory and pro-thrombotic state. An im-
portant group of pharmacological targets for the
treatment of metabolic syndrome are the peroxisome
proliferator activated receptors (PPARs). PPARs are
ligand-activated transcription factors belonging to the
superfamily of nuclear receptors, which include nu-
merous cellular receptors for nutrients and steroids.
So far, three PPAR isotypes (a, b/d, g) have been
identified in a wide range of species, each displaying a
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different tissue distribution and ligand specificity [1].
PPARs share a similar structure and a common
molecularmechanismof action by forming an obligate
heterodimer with the 9-cis retinoic acid receptor
RXR. PPAR-RXR heterodimers selectively bind
genomic sequences consisting of a direct repeat of
the hexameric nucleotide sequence AGGTCA sepa-
rated by 1 nucleotide (Direct Repeat-1). These so-
called peroxisome proliferator response elements
(PPRE) are located in the promoter of PPAR target
genes or in intronic regions [2–5].
The PPARa isotype (NR1C1) is highly expressed in
liver, and governs the adaptive response to fasting [6–
8]. PPARa is an extremely important regulator of
hepatic nutrient metabolism including fatty acid
oxidation (peroxisomal and mitochondrial), fatty
acid uptake, amino acid metabolism, glycerol metab-
olism, and lipoprotein assembly and transport [9–11].
In addition, PPARa potently suppresses the hepatic
inflammatory response [12, 13], an effect that is also
observed in extra-hepatic tissues such as the vascular
wall [14].Much less is known about the role of PPARa
in other tissues, although evidence is accumulating
that PPARa induces cardiac and skeletal muscle fatty
acid oxidation [15, 16]. Importantly, PPARamediates
the effects of hypolipidemic fibrate drugs, which
decrease plasma triglycerides and increase plasma
HDL concentrations. In contrast to PPARa, PPARg
(NR1C3) is highly expressed in white adipose tissue
(WAT), where it promotes lipid storage. PPARg is a
key transcription factor in the adipogenesis program
and is essential for adipocyte survival [17, 18]. It also
serves as the molecular target for the thiazolidine-
dione (TZD) class of insulin-sensitizing drugs that are
widely used in the treatment of type 2 diabetes.
PPARg promotes whole body glucose utilization;
however, it has been difficult to identify themolecular
mechanisms behind this effect. Much of the attention
has been focused on possible cross-talk between
adipose tissue and skeletal muscle, as muscle is
responsible for the major share of whole body glucose
utilization. However, adipose tissue is a large organ,
especially in the obese, and accordingly it can also be
envisioned that the insulin-sensitizing effect of TZDs
on glucose uptake is partially exerted at the adipose
tissue level.
While PPARa and PPARg have been extensively
studied overmany years, much less is known about the
function of the PPARb/d isotype (NR1C2). Studies
with genetically modified PPARb/d mice have illus-
trated the importance of this nuclear receptor inWAT
and skeletal muscle, two organs that have a key role in
glucose homeostasis [19–22]. It was shown that
activation of PPARb/d in adipose tissue protects
against adiposity and hyperlipidemia by inducing
fatty acid catabolism [21]. Moreover, pharmacologi-
cal activation as well as specific constitutive over-
expression of PPARb/d leads to a shift in muscle fiber
composition towards type I muscle fibers, resulting in
increased muscle oxidative capacity [20, 22]. PPARb/
d has also been shown to stimulate hepatic VLDL
production, influence wound healing, and affect colon
carcinogenesis [23–25]. However, whether PPARb/d
has a functional role in glucose homeostasis, in
analogy with other PPAR isotypes, remains to be
firmly established.
Here we show that glycogen synthase 2 (Gys-2), the
rate-limiting enzyme for glycogen synthesis in liver
and adipose tissue, is a target gene of PPARa, PPARb/
d and PPARg. Transcriptional regulation is achieved
via a PPAR response element present in the first
intron. We show that an additional direct repeat
response element identified in the Gys-2 promoter
mediates transactivation by hepatic nuclear factor 4a
(HNF4a).
Materials and methods
Chemicals. Wy14643 was obtained from Eagle Picher Technologies
laboratories (Lenexa, KS, USA). Rosiglitazone was from Alexis
(Breda, The Netherlands). SYBR Green was from Eurogentec
(Seraing, Belgium). Dulbeccos modified Eagles medium (DMEM),
fetal calf serum (FCS), calf serum and penicillin/streptomycin/
fungizone were from Cambrex Bioscience (Seraing). Otherwise,
chemicals were from Sigma (Zwijndrecht, The Netherlands).
Animal experiments. PPARb/d mutant null mice (PPARb/d–/–)
and PPARg heterozygous mice (PPARg+/–) were on a mixed
background (Sv129/C57BL/6) and have been described previously
[26, 27]. Wild-type littermates served as control animals.
PPARa–/– mice and corresponding wild-type mice on an Sv129
background were purchased at Jackson Laboratories (Bar Harbor,
ME, USA). Liver-specific hepatocyte nuclear factor 4a (HNF4a)-
null mice were generated as described previously. Livers were
collected from 45-day-old HNF4aflox/flox X albumin-Cre+ (KO) and
HNF4aflox/flox X albumin-Cre– (FLOX) mice [28]. Mice were
maintained at 208C with a 12-h light-dark cycle. All mice were
between 3 and 6 months of age. For the fasting experiment, 3-
month-old male mice were fasted for different periods of time
starting at the onset of the light cycle. For the refeeding experiment,
mice were fasted for 24 h after which they were put back on chow
for 7 h before sacrifice. After sacrificing the animals, tissues were
immediately frozen in liquid nitrogen. The animal experiments
were approved by the animal experimentation committee of
Wageningen University or the Etat de Vaud (Switzerland).
Oligonucleotide micro-array. Total RNA was prepared from
epididymal WATof wild-type and PPARb/d–/– mice (five animals
of each genotype) using TRIzol reagent (Invitrogen, Breda, The
Netherlands) and subsequently pooled per group. PooledRNAwas
further purified usingQiagenRNeasy columns, and the quality was
verified using Bioanalyzer 2100 (Agilent, Amsterdam). For one
cycle cRNA synthesis (Affymetrix, Santa Clara, USA) 10 mg of
RNAwas used.Hybridization, washing and scanning ofAffymetrix
GeneChipmouse genome 430 2.0 arrays was according to standard
Affymetrix protocols. Fluorimetric data were processed by Affy-
metrix GeneChip operating software and the gene chips were
globally scaled to all the probe sets with an identical target intensity
value. Further analysis was performed by Data Mining Tool
(Affymetrix).
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3T3-L1 adipogenesis assay. 3T3-L1 fibroblasts were grown in
DMEM plus 10% calf serum and plated for final differentiation
in DMEM plus 10% FCS. At 2 days after reaching confluence, the
medium was changed and the following compounds were added:
isobutyl methylxanthine (0.5 mM), dexamethasone (1 mM), and
insulin (5 mg/mL). After 3 days, the medium was changed to
DMEM plus 10% FCS and insulin (5 mg/mL). After 6 days the
medium was changed to DMEM plus 10% FCS, which was
changed every 3 days.
Primary mouse or rat hepatocyte isolation. Primary mouse and rat
hepatocytes were isolated as described previously [29]. Briefly,
after cannulation of the portal vein, the liver was perfused with
calcium-free HBSS, which was pre-gassed with 95% O2 /5% CO2.
Next, the liver was perfused with a collagenase solution until
swelling and degradation of the internal liver structure was
observed. The hepatocytes were released, filtered and washed
several times using Krebs buffer. The viability was assessed by
tryptan blue staining and was at least 80%. Cells were cultured in
Williams Medium E supplemented with 10% FCS, penicillin/
streptomycin/fungizone, insulin and dexamethasone. Cells were
plated in collagen (Serva Feinbiochemica, Heidelberg, Germany) -
coated wells with a density of 0.5106 cells/ml. After 4 h of
incubation, the medium was removed and replaced with fresh
medium. The next day, hepatocytes were used for experiments.
RNA isolation, reverse-transcription, and real-time quantitative
PCR. Total RNAwas extracted from tissues with TRIzol reagent
(Invitrogen); 1 mg total RNA was then reverse-transcribed with
iScript (Bio-Rad, Veenendaal, TheNetherlands). cDNAwas PCR-
amplified with Platinum Taq DNA polymerase (Invitrogen) on a
Bio-Rad iCycler orMyIQ PCRmachine. Primers were designed to
generate a PCR amplification product of 100–200 bp and were
taken from Primerbank (http://pga.mgh.harvard.edu/primerbank/
). Specificity of the amplification was verified by melt curve
analysis and evaluation of efficiency of PCR amplification.
Expression was related to the control gene 36B4, which did not
change under any of the experimental conditions studied.
The following primer pairs were used: mGys-2 (forward):
CCAGCTTGACAAGTTCGACA, mGys-2 (reverse): AT-
CAGGCTTCCTCTTCAGCA, m36B4 (forward):
AGCGCGTCCTGGCATTGTGTGG, m36B4 (reverse):
GGGCAGCAGTGGTGGCAGCAGC, mPPARa (forward):
TATTCGGCTGAAGCTGGTGTAC, mPPARa (reverse):
CTGGCATTTGTTCCGGTTCT, mPPARb (forward):
TTGAGCCCAAGTTCGAGTTTG, mPPARb (reverse):
CGGTCTCCACACAGAATGATG, mPPARg (forward): CA-
CAATGCCATCAGGTTTGG, mPPARg (reverse):
GCTGGTCGATATCACTGGAGATC.
Transactivation assay. The proximal part of the mouse Gys-2
promoter was PCR amplified from mouse genomic DNA (strain
C57BL/6) using the forward primer: 5’ CTTGCTGCCTTTCAG-
GAGAGGGCAG 3’ and reverse primer: 5’ TTCTCTTTAGC-
CATTAAGATAG3’. The resulting 553-bp fragmentwas used for a
second PCR amplification step introducingHindIII andKpnI sites,
which were used for subcloning into the pGL-3 Basic vector
(Invitrogen).
A 156-bp nucleotide fragment surrounding the putative PPRE
within the mGys-2 promoter was PCR amplified from mouse
genomic DNA (strain C57BL/6) and subcloned into KpnI/BglII
sites of the pGL3 SV40 promoter vector (pGL3-tk-LUC, Promega,
Leiden, The Netherlands) using the forward primer: 5AAATCG-
CAGCTGAAACCT 3’, and reverse primer: 5’
CTCCTGCTTGTGCTTCTGC 3’. A 314-nucleotide fragment
surrounding the putative PPRE within intron 1 of the mouse
Gys-2 gene was PCR amplified from mouse genomic DNA (strain
C57BL/6) and subcloned into theKpnI andBglII sites of the pGL-
Tk-Luc reporter gene. Reporter vectors were transfected into
human hepatoma HepG2 cells, together with an expression vector
(pSG5) for mPPARa, mPPARb, or mPPARg1, in the presence or
absence of Wy14643 (50 mM), L-165041 (5 mM), or rosiglitazone
(5 mM), respectively. Transfections were carried out using the
calcium-phosphate precipitation method. A b-galactosidase re-
porter vector was co-transfected to normalize for differences in
transfection efficiency. Luciferase activity was measured 24 h post
transfection using the Promega luciferase assay kit (Promega) on a
Fluoroskan Ascent Fl apparatus (Thermo labsystems, Breda, The
Netherlands). b-Galactosidase activity was measured in the cell
lysate by a standard assay using 2-nitrophenyl-bD-galactopyrano-
side as a substrate. To disable the mouse Gys-2 PPRE within the
mGys-2 promoter, two separate (A and B) partially overlapping
PCR fragments were generated using the wild-type mGys-2
promoter as a template. Primers sets used to generate part A of
the mutated mGys-2 promoter fragment were: 5’-
TTTGGTCTAAAGGCCTTTGGCCAAAGG-3’ and 5’-
CTTGCTGCCTTTCAGGAGAGGGC
AG-3’. Primers sets used to generate part B of themutatedmGys-2
promoter fragment were: 5’-CCTTTGGCCAAAGGCCTTTA-
GACCAAA-3’ and 5’-TTCTCTTTAGCCATTAAGATAGG-
GATTG-3’. PCR was carried-out using the two upper DNA
fragments and the following primers: 5’-
cccaagcttCTTGCTGCCTTTCAGGAG-3’ and 5’-
ggggtaccTTCTCTTTAGCCATTAAGATAG-3’. The PCR frag-
ment was subsequently cloned into the pGL3 basic reporter vector
(HindIII/KpnI cloning site) and verified by automated sequencing.
The hHNF4a expression plasmid was constructed by amplifying
human hepatoma HepG2 cDNA using the following primers,
forward primer 5’-GAATGCGACTCTCCAAAACC-3’ and re-
verse primer 5’-ATCCTTCCCATTCCTGCTCT-3’, followed by
subcloning of the resulting PCR product into an pGEM-Teasy
vector (Promega). The insert was excised by NotI digestion and
further subcloned into pcDNA3.1/V5-HisA (Invitrogen). The
nucleotide sequence was verified by automated sequencing.
Gel shift. hRXRa and mPPARg proteins were generated from
pSG5 expression vectors, using the TNT coupled in vitro tran-
scription/translation system (Promega). The following oligos were
annealed to generate the double-stranded DNA probe; for DR-
1int: 5’-CAGGACTTTGGTGACCTCTGGCCTATAT-3’ and 5’-
ACACATATAGGCCAGAGGTCACCAAAGTC-3’. For nonspe-
cific competition, the following primers were used: etsF 5’-
TGGAATGTACCGGAAATAACACCA-3’, etsR 5’-
TGGTGTTATTTCCGGTACATTCCA-3’. Oligonucleotides
were annealed and labeled by Klenow filling (New England
Biolabs, Leusden, The Netherlands) using Redivue [a-32P]dCTP
(3000 Ci/mmol; Amersham, Roosendaal, The Netherlands). In
vitro-translated proteins (0.5–0.8 ml/reaction) were pre-incubated
for 15 min on ice in 1 binding buffer (80 mM KCl, 1 mM DTT,
10 mMTris-HCl pH 7.4, 10% glycerol, plus protease inhibitors) in
presence of 2 mg poly[dI.dC], 5 mg sonicated salmon sperm DNA
and competitor oligonucleotides in a final volume of 20 ml. Then
1 ng (1 ng/ml) of radiolabeled oligo was added and incubation was
continued for another 10 min at room temperature. Complexes
were separated on a 4% polyacrylamide gel (acrylamide/bisacry-
lamide 37.5:1) equilibrated in 0.5 TBE at 25 mA.
Chromatin immunoprecipitation. Chromatin immunoprecipita-
tion (ChIP) on 3T3-L1 cells and mouse liver was carried out as
described previously [11]. Sequences of primers used for PCRwere
5’-TCTGGCAGGCATAAGGACCCGAGTT-3’ and 5’-
GGAAGCCAGGACAGAGTGCAAATACAAT-3’ for DR-1int
(Intron). For DR-1prom, the following primers were used: 5’-
AAAACTGCTTGTGTCTGAGGGAAAC-3’ and 5’-AGAG-
GACAGACTGAGCATGACAAGAG-3’. Control primers used
were 5’-GCTGCGAGATCCATCACCCACTAAAC-3’ and 5’-
AGCCATCTCACCAGCCCCAACTT-3’. Antibodies against
PPARs were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). ChIP on rat hepatocytes was done using a commercially
available kit (Active Motif, Rixensart, Belgium). The HNF4a
antibody was from Tebu-Bio (Heerhugowaard, The Netherlands).
The primers used to amplify the sequence surrounding the DR-
1promwere 5’-GAATGCCGCTGTGCCTGAGGGAAAC-3’ and
5’-AGAGGACAGAAGAAGAGTGACAAGAG-3’. For DR-
1int: 5’-TCTGTCAGGCATAAGGACCTGGGTT-3’ and 5’-
ATTGTATTTGAACTCTGTCCTGGTCTCT-3’.
Histology. Liver tissue from wild-type and PPARa–/– mice was
embedded in Tissue-Tek O.C.T. compound from Sakura Finetek
(Zoeterwoude, TheNetherlands) and frozen. Cryosections of 5 mm
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from frozen liver were made and analyzed for glycogen accumu-
lation using the periodic acidSchiff (PAS) reaction. Hematoxylin
and eosin staining of liver cryosections was done using standard
protocols.
Western blot. A mouse anti-glycogen synthase monoclonal anti-
body was used (clone GS-7H5 MAB3106) (Chemicon Interna-
tional, Hampshire, UK). Western blotting was carried out as
previously described [4]. The primary antibody was used at a
dilution of 1:1000 and the secondary antibody (anti-mouse IgG,
Dako, Glostrup, Denmark) was used at a dilution of 1:8000.
Results
Expression of Gys-2 in WAT is regulated by PPARs.
Our initial aim was to identify novel putative target
genes of PPARb/d inWAT.Accordingly, we compared
gene expression in WAT of wild-type versus PPARb/
d–/– mice using Affymetrix micro-array analysis. The
expression of several genes involved in glucose and
lipid metabolism was down-regulated in PPARb/d–/–
mice, including PPARg, PGC-1a, and GLUT4, which
was confirmed for several genes by real-time quanti-
tative PCR (qPCR) (Table 1). Expression of Gys-2
was most significantly down-regulated in PPARb/d–/–
mice, and therefore Gys-2 was selected for more
detailed investigation. Q-PCR confirmed the marked
down-regulation of Gys-2 mRNA in WATof PPARb/
d–/– mice (Fig. 1a). Furthermore, expression of Gys-2
also appeared to be down-regulated in WAT of
PPARg+/– and PPARa–/– mice, although the former
result did not achieve statistical significance. In
PPARb/d–/– mice, the decrease in Gys-2 mRNAwas
paralleled by a significant down-regulation of PPARa
and PPARg expression, while in PPARa–/– mice
expression of PPARb/d was significantly down-regu-
lated (Fig. 1b). These data show that PPARs are
crucial for maintaining Gys-2 expression in fat,
although it is difficult to ascertainwhichPPAR isotype
is the main regulator of Gys-2 expression in WAT.
To investigate whether expression of Gys-2 in adipo-
cytes is under direct control of PPARs, the effect of
Figure 1. Expression of Glyco-
gen synthase 2 (Gys-2) in white
adipose tissue (WAT) is regulat-
ed by peroxisome proliferator-
activated receptors (PPARs).
Expression of Gys-2 (a) and
PPARs (b) in WAT of PPARb/
d–/– mice, PPARg+/– mice, and
PPARa–/– mice, as determined
by qPCR. The effects of PPAR
deletion were evaluated by Stu-
dents t-test (* p<0.05; **
p<0.01). Error bars represent
SEM (n=5). (c) Differentiated
3T3-L1 adipocytes were treated
with the synthetic PPARg ago-
nists rosiglitazone or ciglitazone,
or the PPARb/d agonist L165041
for 24 h. Expression of Gys-2 was
determined by qPCR. Expres-
sion of cells treated with vehicle
(DMSO) was set at 1. Data
shown are representative results
from three independent experi-
ments. (d) Gys protein expres-
sion was analyzed in lysates from
3T3-L1 adipocytes treated with
either PPARb/d (L165041,
2.5 mM) or PPARg (rosiglita-
zone, 1 mM) agonist.
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PPAR ligands on Gys-2 mRNAwas studied in differ-
entiated mouse 3T3-L1 adipocytes. It was observed
that the PPARb/d agonist L165041, and the PPARg
agonists ciglitazone and rosiglitazone significantly
induced Gys-2 mRNA levels (Fig. 1c). This effect
was confirmed at the protein level (Fig. 1d). Thus,
Gys-2 may represent a direct target gene of PPARg
and PPARb/d in adipocytes.
PPARa governs Gys-2 hepatic expression. A link
between PPARs and glycogen has been previously
made. It was observed that liver glycogen levels were
reduced in refed PPARa–/– mice compared to refed
wild-type mice [30, 31], which we confirmed using
histochemical staining (Fig. 2). Furthermore, hepatic
expression of Gys-2 was decreased in PPARa–/– mice
[32]. Expression of Gys-2 is highest in liver, followed
by WAT (our unpublished data). We confirm that
hepatic Gys-2 mRNA is markedly reduced in
PPARa–/– mice; however, only in the 24-h fasted
and refed state (Fig. 3a). To further examine the role
of PPARa in Gys-2 expression, primary hepatocytes
from wild-type and PPARa–/– mice were treated with
the synthetic PPARa agonist Wy14643, allowing for a
Figure 2. Staining for hepatic
glycogen is higher in refed wild-
type mice compared to refed
PPARa–/– mice. (a) Representa-
tive hematoxylin and eosin stain-
ing of liver from two wild-type
and two PPARa–/– mice. (b)
Representative PAS staining of
liver from two wild-type and two
PPARa–/– mice. Mice were fast-
ed for 24 h followed by refeeding
for 7 h before sacrifice.
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direct evaluation of the effect of PPARa activation on
Gys-2 expression. Basal expression of Gys-2 was
about fourfold reduced in PPARa–/– hepatocytes,
indicating a requirement for PPARa (Fig. 3b). Fur-
thermore, Wy14643 stimulated Gys-2 expression in
wild-type but not in PPARa–/– hepatocytes (Fig. 3b).
Induction of Gys-2 expression by synthetic PPARa
agonists was also observed in rat primary hepatocytes
(Fig. 3c). Together, these data suggest a direct role of
PPARa in governing hepatic Gys-2 expression.
Identification of a putative PPRE in the proximal
promoter of the mouse Gys-2 gene. To determine
what genomic region could be responsible for the
PPAR-induced up-regulation of Gys-2 mRNA, the
mouse Gys-2 gene was scanned for potential PPREs
(NUBIScan algorithm and Hidden Markov Model
framework) [33, 34]. A Direct Repeat-1 motif (DR-
1prom) was localized to the proximal Gys-2 gene
promoter, about 169 bp upstream from the transcrip-
tion start site. With the exception of two nucleotides,
DR-1prom is identical to the consensus sequence,
suggesting that this sequence could serve as a func-
tional PPRE (Fig. 4a). DR-1prom was conserved
between mouse and rat.
To examine whether the promoter region containing
the putative PPRE is responsible for PPAR-depend-
ent up-regulation of Gys-2 expression, a 553-nucleo-
tide fragment of the mouse Gys-2 promoter gene was
cloned in front of a luciferase reporter gene and
transactivation studies were carried out in HepG2
cells. Surprisingly, co-transfection of PPARa or
PPARg1 expression vectors in combination with
PPAR agonists slightly decreased luciferase activity,
while PPARb/d activation had little effect (Fig. 4b).
Transactivation assays performed with a small ge-
nomic fragment surrounding DR-1prom cloned in
front of SV40-luciferase led to a similar overall PPAR-
mediated repression for PPARa and PPARg1, while
PPARb/d had little effect (Fig. 4c). Co-transfection of
RXR or of different co-activators such as CBP and
PGC1a did not change this pattern (data not shown).
Thus, the PPRE identified in the Gys-2 promoter
probably does not mediate the effect of PPARs on
Gys-2 expression. Nevertheless, ChIP experiments
carried out in 3T3-L1 cells indicated that (1) PPARg
was bound toDR-1prom inmature adipocytes, but not
in pre-adipocytes (Fig. 4d), and (2) PPARb/d was
bound to DR-1prom in pre-adipocytes and, more
strongly, in mature adipocytes (Fig. 4e). Thus, despite
DR-1prom behaving poorly as a PPRE in classical
transactivation assay, it binds both PPARg and
PPARb/d in adipocytes. This suggests that in vivo
binding of PPARg and PPARb/d to DR-1prom does
not translate into transcriptional activation of the
Gys-2 gene, and accordingly that activation of Gys-2
expression by PPARs may be mediated by another
genomic region. It should be mentioned that ChIP did
not reveal any binding of PPARa to DR-1prom in
hepatocytes (data not shown).
Interestingly, using the same strategy as described
above, a putative PPRE that is homologous to the
consensus DR-1 sequence was identified in intron 1 of
the mouse Gys-2 gene (Fig. 4a). To assess whether
DR-1int was able to mediate PPAR-dependent trans-
activation, a 314-nucleotide genomic fragment sur-
rounding DR-1int was cloned in front of the SV40
promoter followed by a luciferase reporter gene. In
HepG2 cells treatment with the synthetic PPARa
agonist Wy14643 induced reporter activity and this
activation was further enhanced upon co-transfection
of mPPARa (Fig. 5a). Similar inductions of reporter
Figure 3. PPARa governs hepatic expression of Gys-2. (a) Rela-
tive expression of Gys-2 in fed, fasted and refed wild-type and
PPARa–/–mice, as determined by qPCR.Micewere fasted for 0, 6,
12 or 24 h, with refeeding for 7 h following 24 h fasting. Significant
differences between wild-type and PPARa–/– mice were observed
in the 24-h fasted and the refed state (b) Relative expression of
Gys-2 in freshly isolated wild-type and PPARa–/– hepatocytes
treated for 24 h with vehicle (DMSO) or Wy14643 (10 mM), as
determinedbyqPCR.Significant effectswere observedby two-way
ANOVA for genotype (p<0.001), and for the interaction between
the genotype and Wy14643 (p<0.05). (c) Relative expression of
Gys-2 in freshly isolated rat hepatocytes which were treated for
24 h with either vehicle (DMSO), Wy14643 (50 mM) or fenofibrate
(50 mM). The effects of Wy14643 and fenofibrate were statistically
significant (Students t-test: p<0.01). Error bars represent SEM.
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activity were observed for PPARb/d and PPARg and
their respective agonists (Fig. 5a). Thus, DR-1int is
able to mediate PPAR-dependent transactivation,
irrespective of the PPAR isotype, suggesting that it
may at least be partially responsible for PPAR-
dependent regulation of Gys-2 expression.
In agreement with the transactivation data, PPARa,
PPARb/d and PPARg proteins were able to specifi-
cally bindDR-1int in gel shift experiments.A retarded
heterodimeric complex was observed only in the
presence of both PPAR and obligate binding partner
RXRa (Fig. 5b). The complex disappeared in the
presence of an excess of cold specific oligonucleotide,
but not nonspecific oligonucleotide.
Examination of in vivo PPAR binding to DR-1int by
ChIP yielded very similar results as for DR-1prom:
PPARg was bound to DR-1int in mature 3T3-L1
adipocytes, but not in pre-adipocytes (Fig. 6a), where-
as PPARb/d was bound to DR-1int in both pre- and
mature adipocytes (Fig. 6b). In liver, ChIP analysis
demonstrated binding of PPARa to DR-1int in wild-
type but not PPARa–/– mice, and binding was en-
hanced by fasting and Wy14643 (Fig. 6c). Together,
these data indicate that mouse Gys-2 is a direct PPAR
target gene and that regulation by PPARs is at least
partially mediated by a PPRE present in intron 1.
Gys-2 is a novel direct target of the liver enriched
factor HNF4a. As explained above, PPARa caused a
reduction in Gys-2 promoter activity via DR-1prom
(Fig. 4b, c). A similar decrease of promoter activity in
response to PPARa despite the presence of a putative
PPRE has been reported for other genes. Indeed, it
was found that PPARa decreases expression of the
Table 1. Genes involved in glucose and lipid metabolism that were differentially expressed between white adipose tissue of wild-type and
PPARb/d–/– mice.
Gene Product Fold decrease
Micro-array Q-PCR
Glucose metabolism
Gys2 glycogen synthase 2 13.27 9.28
Pik3r1 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 2.99
Pik3r1 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 2.64
Gys3 glycogen synthase 3, brain 2.25
Ppp1r3c protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen 2.19
Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 2.16 1.56
Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 2.04 1.56
PFK-2 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2.01
Gdc1 glycerol phosphate dehydrogenase 1, cytoplasmic adult 1.93
Ppp1r3c protein phosphatase 1, regulatory subunit 3C, protein targeting to glycogen 1.91
Gdc1 glycerolphosphate dehydrogenase 1, cytoplasmicadult 1.84
Pygl liver glycogen phosphorylase 1.71
Lipid metabolism
Pparg peroxisome proliferator activator receptor gamma 2.99 3.63
C5D sterol-C5-desaturase 2.85
Lrp1 low density lipoprotein receptor-related protein 1 2.22
Cd36 CD36 antigen 2.20 3.09
Fads3 fatty acid desaturase 3 2.06
Lipe lipase, hormone sensitive 1.96 1.66
Lrp2 low density lipoprotein receptor-related protein 2 1.91
Fabp5 fatty acid binding protein 5, epidermal 1.87
Dgat1 diacylglycerol acyltransferase 1.87
Decr1 2,4-dienoyl CoA reductase 1, mitochondrial 1.85
Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 1.85
Phyh phytanol-CoA hydroxylase 1.77
Dgat2/1 diacylglycerol O-acyltransferase 2-like 1 1.75
Ppargc1 peroxisome proliferative activated receptor, gamma, coactivator 1 1.74 1.97
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apoCIII and transferrin genes via competition with
the HNF4a. Since HNF4a is known to recognize DR-
1 sequences as well, we examined whether HNF4a
might control the expression ofGys-2 in liver, possibly
via DR-1prom. Gys-2 mRNA levels were markedly
decreased in liver-specific HNF4a-null mice, thus
supporting a role for HNF4a in regulating Gys-2
expression (Fig. 7a). In transactivation assays using
the Gys-2 promoter, HNF4a markedly activated
reporter activity, suggesting the presence of a
HNF4a response element within the 0.55-kb promot-
er fragment (Fig. 7b).MutatingDR-1prom resulted in
an approximately 50% reduction in HNF4a-depend-
ent activation of the Gys-2 promoter (Fig. 7c), which
suggests that (a) HNF4a responsiveness is partially
mediated by DR-1prom, or (b) the mutations with
DR-1prom only partially disabled HNF4a respon-
siveness. Regardless of these explanations, these data
suggest that HNF4a directly regulates the hepatic
expression of Gys-2 at least partially via DR-1prom.
Finally, ChIP clearly showed HNF4a binding to DR-
1prom but not DR-1int in rat primary hepatocytes
(Fig. 7d).
Cross-talk between PPARa and HNF4a in the tran-
scriptional control of Gys-2. Whereas HNF4a acti-
vates the Gys-2 promoter via DR-1prom, PPARa
does the opposite, suggesting that PPARa may
interfere with Gys-2 promoter activation by HNF4a.
To examine whether this is the case, the effect of
PPARa on HNF4a-mediated transactivation of the
0.55-kb Gys-2 promoter was studied. PPARa activa-
Figure 4. The DR-1 present in the Gys-2 promoter does not mediate PPAR-dependent transactivation. (a) Alignment of the consensus
PPREsequencewith the sequenceof rat andmouseGys-2DR-1promandGys-2DR-1int. (b)HepG2cellswere transfectedwith a reporter
vector containing a 553-nucleotide fragment of the proximal mouse Gys-2 promoter gene and PPAR expression vectors. (c) HepG2 cells
were transfected with a SV40 reporter vector containing an isolated 156-nucleotide fragment surrounding DR-1prom of the proximal
mouse Gys-2 promoter gene and PPAR expression vectors. Luciferase and b-galactosidase activities were determined 24 h after exposure
of the cells to different PPARagonists: 50 mMWy14643, 5 mML-165041 and 10 mMof rosiglitazone. Error bars represent SEM.Chromatin
immunoprecipitationofDR-1promusing antibodies againstmPPARg (d) ormPPARb/d (e). The gene sequence spanningDR-1promand a
random control sequence were analyzed by PCR in the immunoprecipitated chromatin of 3T3-L1 preadipocytes and mature adipocytes.
Preimmune serum was used as a control. PI, preimmune serum, Cntl, random control sequence. (f) Schematic overview of localization of
primers used for amplification of immunoprecipitated DNA.
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tion significantly reduced HNF4a-dependent trans-
activation, indicating competition between HNF4a
and PPARa in the regulation of the Gys-2 promoter
(Fig. 7e). As already mentioned above, we failed to
find any evidence for binding of PPARa toDR-1prom
in hepatocytes. Thus, the inhibitory effect of PPARa
on transcriptional activation of Gys-2 by HNF4a
likely does not occur via competition with HNF4a for
actual binding to DR-1prom.
Discussion
In the present study, we have identified the mouse
Gys-2 gene as a direct PPAR and HNF4a target gene.
We have shown that the effects of PPARs andHNF4a
on Gys-2 expression occur via two distinct response
elements. Indeed, while transcriptional activation of
theGys-2 gene byPPARswas found to bemediated by
a PPRE present in intron 1 of the mGys-2 gene (DR-
1int), the stimulatory effect of HNF4a was mediated
by a response element in the immediate upstream
promoter (DR-1prom).
Our data are suggestive of the following scenario. In
liver, which expresses high amounts of HNF4a, DR-
1prom is occupied by HNF4a but not PPARa, while
DR-1int is bound by PPARa but not HNF4a. Hence,
HNF4a and PPARa activate Gys-2 expression via
different response elements. Nevertheless, important
negative cross-talk between the two nuclear receptors
was observed. In the absence of any mutual binding to
the response elements, it can be hypothesized that
competition may take place at the level of binding to
common co-activator proteins in a mechanism that is
often referred to as squelching. In adipose tissue,
which does not express HNF4a, DR-1prom is occu-
pied by PPARb/d and PPARg, but this does not result
in transcriptional activation. Rather, transactivation
occurs via binding of PPARb/d and PPARg to DR-
1int.
Our data indicate that HNF4a is an extremely
powerful activator of mouse Gys2 transcription,
explaining the marked reduction in hepatic Gys-2
expression in liver-specific HNF4a-null mice [35] .
As mentioned above, regulation of mGys-2 expres-
sion by HNF4a at least partially occurs via DR-
1prom. A recent study that combined ChIP with
promoter micro-arrays showed that the Gys-2
promoter is bound by HNF4a in human liver [36] ,
thus establishing Gys-2 as a direct target of HNF4a
in human as well. It is not very clear why disabling
the DR-1prom reduced HNF4a-dependent trans-
activation by only 50%. It is possible that the 0.55-
kb Gys-2 promoter fragment contains an additional
HNF4a response element, although in silico anal-
ysis failed to reveal such an element. Alternatively,
Figure 5. Gys-2 up-regulation by PPARs is mediated by a PPRE present in intron 1 of the Gys-2 gene (DR-1int). (a) HepG2 cells were
transfected with a 314-nucleotide fragment of intron 1 of the mouse Gys-2 gene and PPAR expression vectors. Luciferase and b-
galactosidase activities were determined 24 h after exposure of the cells to different PPAR agonists: 50 mMWy14643, 5 mML-165041 and
10 mMrosiglitazone. Error bars represent SEM. (b) Binding of the PPAR/RXRheterodimers toDR-1int as determined by gel shift assays.
A double-stranded response element containing Gys-2 DR-1int was incubated with in vitro transcribed/translated mPPARa protein (left
panel), mPPARb/d protein (middle panel) and mPPARg1 protein (right panel) together with in vitro transcribed/translated hRXRa
protein. Fold excess of specific (malic enzyme PPRE) or nonspecific (ETS oligonucleotide) cold probe is indicated.
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it is possible that mutating the wild-type DR-1prom
(AGGCCAAAGGCCA) into a mutated DR-
1prom (AGGCCTTTGGCCA) only partially dis-
abled the response element.
While functional PPREs are commonly locatedwithin
regulatory sequences, i.e. , proximal promoters,
PPREs have also been identified in intronic sequen-
ces. Examples are PPREs within intron 3 of human/
mouse Angptl4 and rat peroxisomal thiolase B genes,
and within intron 1 of the rat acyl-CoA binding
protein gene and human carnitine palmitoyltransfer-
ase 1A [2–5]. Our data demonstrate that regulation of
Gys-2 expression by PPARs is also mediated by an
intronic PPRE.
In the past few years, our understanding of the
function of PPARb/d in vivo has improved greatly
thanks to studies using various transgenic mouse
models [19, 37]. At the level of metabolism, PPARb/
d over-expression promotes skeletal muscle fatty
acid oxidation and type I fiber content in mice,
resulting in improved endurance exercise perform-
ance [22]. Conversely, deletion of PPARb/d in
cardiomyocytes is associated with impaired fatty
acid oxidation and expression of fatty acid oxidative
genes, whereas glucose uptake is increased [38]. In
WAT, PPARb/d stimulates fatty acid oxidation and
uncoupling, thereby diminishing adiposity [21]. It is
thus clear that PPARb/d plays a pivotal role in
governing fatty acid oxidation in a variety of tissues.
In contrast, data linking PPARb/d to regulation of
glucose homeostasis remain scarce [20, 39, 40] . Our
data reveal that PPARb/d is a critical regulator of the
adipose expression of the Gys-2 gene. Furthermore,
micro-array and qPCR analysis indicated that ex-
pression of numerous other genes involved in lipid
and glucose metabolism was markedly down-regu-
lated in PPARb/d-null mice, including GLUT4, p85,
and CD36. Since PPARg and PGC-1a were signifi-
cantly down-regulated as well, it is possible that
many of the observed changes are not linked to the
absence of PPARb/d per se but rather reflect indirect
effects mediated via decreased PPARg and PGC-1a
mRNA. Although such an effect may contribute to
some extent to the down-regulation of Gys-2 in
PPARb/d-null mice, the in vitro studies leave no
doubt that Gys-2 is a direct target gene of PPARb/d,
as well as of PPARg.
Glycogen is stored inmany tissues, yet it is particularly
abundant in liver, muscle, and adipose tissue. In liver,
glycogen serves to maintain blood glucose levels
between meals, while skeletal muscle glycogen is
used to fuel muscle contractions. In contrast, adipose
tissue glycogen serves as a source of glycerol 3-
phosphate, which is required for (re)-esterification of
fatty acids into triglycerides [41]. Several alternative
pathways exist to produce glycerol 3-phosphate,
including synthesis from glucose, and conversion of
gluconeogenic precursors (glyceroneogenesis). Since
expression and activity of glycerol kinase are very low
in adipose tissue [42], direct phosphorylation of
glycerol is not considered as a major pathway to
generate glycerol 3-phosphate. However, recent stud-
ies suggest that this may change after treatment with
synthetic PPARg agonists, which markedly up-regu-
late glycerol kinase expression in human and mouse
adipocytes [11, 42]. In fact, it has been hypothesized
that stimulation of glycerol kinase expression by
Figure 6. PPARg, PPARb/d, and PPARa bind to the Gys-2 DR-
1int in vivo. Chromatin immunoprecipitation of Gys-2 DR-1int
using antibodies against mPPARg (a), mPPARb/d (b) or mPPARa
(c). The gene sequence spanning DR-1int and a random control
sequence were analyzed by PCR in the immunoprecipitated
chromatin of 3T3-L1 preadipocytes and mature adipocytes (a, b)
or mouse liver (c). Preimmune serum was used as a control. PI,
preimmune serum, Cntl, random control sequence. (d) Schematic
overview of localization of primers used for amplification of
immunoprecipitated DNA.
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TZDs, resulting in increased fatty acid re-esterifica-
tion, may at least partially account for the suppressive
effect of TZDs on plasma free fatty acid levels.
Stimulation of fatty acid esterification is part of a
general lipogenic and adipogenic effect of PPARg in
the adipocyte. Since adipose glycogen stores yield
glycerol 3-phosphate as a precursor for fatty acid
(re-)esterification, up-regulation of Gys-2 expression
byPPARg can be placed in the context of the lipogenic
role of PPARg in the adipocyte, which is aimed at
promoting energy storage.
Besides contributing to lipogenesis, synthesis of
glycogen permits continued uptake of glucose into
cells. Accordingly, it can be speculated that up-
regulation of adipose Gys-2 by PPARgmight partially
account for the stimulation of glucose uptake into
adipocytes by PPARg agonists.
It is currently still ambiguouswhether PPARb/d serves a
general anabolic or catabolic function in the adipocyte.
On the one hand, it has been reported that PPARb/d
promotes fatty acid oxidation in adipocytes [20, 21]. On
the other hand, PPARb/d also seems to have a
facilitative, yet important role in lipo- and adipogenesis
[43]. As discussed above for PPARg, up-regulation of
Gys-2 expression by PPARb/d may indicate a role for
PPARb/d in fatty acid (re-)esterification, thus contribu-
ting to a lipogenic role for PPARb/d.
The highest levels of glycogen are found in liver and
fluctuate with nutritional status. The hepatic synthesis
of glycogen from glucose is catalyzed by Gys-2 [44].
Remarkably, expression of Gys-2 in liver increases
during fasting, at the same time when glycogen stores
are actively broken down [32]. The reason behind this
seemingly counterintuitive regulation is not very
Figure 7. Gys-2 DR-1prom is a
binding site for the nuclear recep-
tor HNF4a. (a) Gys-2 mRNA
levels in liver of liver-specific
HNF4a-null (HNF4a–/–) and
wild-type (FLOX) mice were an-
alyzed by qPCR (n=3 per group).
(b) HepG2 cells were transfected
with a reporter vector containing
553-bp of the mouse Gys-2 prox-
imal promoter and increasing
amounts of hHNF4a expression
vector. (c) HepG2 cells were
transfected with a reporter vector
containing553 bpof thewild-type
and mutated mGys-2 proximal
promoter and hHNF4a expres-
sion vector. (d) Chromatin immu-
noprecipitation of Gys-2 DR-
1prom using antibodies against
HNF4a. Thegene sequence span-
ning DR-1prom and a control
sequence were analyzed by PCR
in the immunoprecipitated chro-
matin of rat primary hepatocytes.
(e) HepG2 cells were transfected
with a reporter vector containing
553 bp of the mouse Gys-2 prox-
imal promoter, an expression vec-
tor for hHNF4a, and increasing
amounts of mPPARa expression
vector. Normalized luciferase ac-
tivity of the mGys-2 reporter
vector in the absence of
mPPARa, hHNF4a and
Wy14643 was set at 1. Error bars
represent SEM.
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clear, but it may serve to prime the glucose synthesiz-
ing system forwhen dietary glucose becomes available
again. In the absence of PPARa, we observed that the
expression of Gys-2 drops markedly during prolonged
fasting and refeeding.The reducedGys-2 expression is
likely responsible for the diminished rate of glycogen
formation upon refeeding, as observed by us and
previously by others. Indeed, the effect of PPARa
deletion on liver glycogen is minor except under
conditions of refeeding [30–32]. It has been reported
that after a short-term fast the gluconeogenic flux in
PPARa-null mice is directed more towards glycogen,
leading to a decrease in hepatic glucose output.
However, it is unclear what happens to the gluconeo-
genic flux toward glycogen in the fasted-refed state,
although our and other data clearly indicate that total
glycogen synthesis is decreased in PPARa–/– mice.
Mutation of the GYS2 gene in humans leads to lower
hepatic glycogen levels and fasting hypoglycemia [45],
biochemical features that are also observed in
PPARa–/– animals [31]. However, opposite to that
observed in patients with a dysfunctional GYS2 gene,
PPARa–/– mice show low plasma ketones, which is
explained by the stimulatory effect of PPARa on fatty
acid oxidation and ketogenesis.
Overall, our data suggest that the decreased hepatic
glycogen levels in PPARa–/– and liver-specific
HNF4a-null mice [28, 35] may be due to decreased
activation of Gys-2 expression via DR-1int and DR-
1prom, respectively. Although PPARa and HNF4a
stimulate Gys-2 expression via different response
elements, important interplay exist between signaling
of the two nuclear receptors.
In conclusion, we show that Gys-2 is a direct target
gene of PPARs. Transcriptional regulation is achieved
via a PPRE present in the first intron. An additional
direct repeat response element identified in the Gys-2
promoter mediates transactivation by HNF4a.
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